ABSTRACT SUBMISSION

Authors are invited to submit abstracts for the upcoming 17th International Symposium on Amyloidosis being held March 1-5, 2020 in Tarragona, Spain. In this biannual meeting, amyloidosis experts present and discuss basic, preclinical and clinical aspects in the field of amyloidosis. The scientific program will include Plenary Sessions, Question and Answer Panels, Hot Topics, Industry-sponsored Symposiums as well as selected oral presentations and abstract posters. We encourage authors to present new research and/or ongoing studies in the biology of treatment of all types of amyloidosis. In order to do so, please be sure to complete all steps of the abstract submission, since only finalized submissions will be evaluated.

All abstracts will be blinded and peer reviewed according to the following points:

  • Is the topic appropriate for the XVII ISA 2020?
  • Does the research meet appropriate scientific merit?
  • Is the study and data of high quality and is the information well organized?
  • Is there an impact of the results on further studies and on clinical practice?

Important dates:

  • Abstract submission deadline is December 15th, 2019 (11:59 pm CET).
  • Authors will be notified in January 13th, 2019 if their abstract has been accepted for presentation at the Symposium.

Presenting authors will be required to register for the XVII International Symposium on Amyloidosis.

ABSTRACT Submission Guidelines

  1. All abstract submissions must be submitted online in WORD format. The Scientific Program Committee will not accept faxed, emailed, mailed submissions or any other format other than WORD.
  2. No changes will be accepted after the abstract submission deadline.
  3. Abstracts  that have been published in their entirety in a Scientific Journal will not be accepted for submission.
  4. All accepted abstract presenters must be registered for the 17th ISA 2020 prior to the meeting.
  5. Travel or registration fees for abstract presenters are not covered.
  6. All complete and finalized abstracts will be reviewed for consideration of oral presentation or poster exhibition.
  7. Please, ensure that your abstract does not contain spelling, grammatical or scientific errors, as it will be reproduced exactly as submitted. No copyediting will be done.
  8. To submit an abstracts following information will be requested:
    • Title: in capital letters and without abbreviations. Commercial names should not be used. The title should be brief (150 characters including spaces), but long enough to identify clearly the nature of the presentation.
    • Authors: surname, and initial of the first name. The first author or presenting author must be identified in the corresponding field, as well as in the list of authors (without limited number of coauthors).
    • Affiliation: department and work center. In case of different affiliations, superscripts will be used for each author.
    • Abstract’s body recommended structure:
      • Introduction/Background
      • Objectives
      • Methods
      • Results (must include specific data). Tables are accepted but not figures.
      • Conclusions

Communications must be anonymous. All information that could identify the authors (names, affiliations, work center, ect) must be indicated in the corresponding fields outside the body of the abstract.

    • The abstracts will have a maximum of 3,000 characters, cumulative, including spaces.
    • Typography: Times New Roman 11pl. Simple space. Please use only symbols recognized by Times New Roman typhography.
    • If you use abbreviations or figures, please, explain the first time. You can register acknowledgments or / and sponsorships.
  1. Keywords – Choose up to three (3) keywords for your abstract.
  2. Choose the category that best characterizes your abstract.
  • Amyloid fibril formation, deposition and clearance
  • Genetics and basic science in amyloidosis
  • Diagnosis and prognosis of AL amyloidosis
  • Treatment of newly diagnosed AL amyloidosis eligible for transplant
  • Treatment of newly diagnosed AL amyloidosis non eligible for transplant
  • Treatment of relapsed/refractory AL amyloidosis
  • Hereditary amyloidosis (ATTR and others)
  • Wild-type ATTR amyloidosis
  • Novel therapies in ATTR amyloidosis
  • Secondary amyloidosis
  • Other forms of amyloidosis
  • Cardiac amyloidosis
  • Organ transplant in systemic amyloidosis

Poster Submission

Presenters will make physical posters to exhibit during dedicated poster sessions and are required to be with their posters during the poster presenting times

Oral Communications

Presenters will make PPT presentation of up to 10 slides. Every presenter will have 10 minutes time: 7.5 minutes for his/her oral presentation plus 2.5 minutes for discussion.

Withdrawal requests

Abstracts may be withdrawn in the abstract submission system before 6 January. Please email isa2020_abstracts@doctaforum.com.

Authors and Presenters

Include the name, e-mail address, and institutional affiliation and location for all co-authors. There is no limit on the number of co-authors. If an author’s name appears on more than one abstract, it must be identical on each abstract.

The submitter must also identify the author who will present the abstract, which is limited to one presenter. All presenters are required to disclose any financial and non-financial conflicts of interests so that continuing education may be provided. This information will be required upon notification of abstract acceptance in January 2020.

An email will be sent to each author to confirm that the submission has been accepted.

Authors who submit multiple abstracts should be prepared to make arrangements for alternative presenters to attend in case more than one abstract is accepted and presentation times overlap.

Responsibility of Abstract Submitters

  • Submission of an abstract constitutes a commitment by the author(s) to present if accepted.
  • By submitting an abstract, the authors certify that they have written consent for use of any recognizable photographs in posters or presentations.
  • All original research involving human subjects or animal studies must adhere to internationally accepted standards for the conduct of research.

Responsibility of Abstract Presenters

  • Assuring that all appropriate financial and non-financial relationship disclosures have been made.
  • Announcing the disclosures before the presentation of the abstract.
  • Presenters must register for the 17th ISA 2020 and are responsible for all registration fees and personal expenses related to the meeting.